Editas Medicine (EDIT) | Stock Overview & Key Data
Editas Medicine Performance Comparison
Stock Range
Today's Range
Low: $2.48
High: $2.69
on August 29, 2025
52 Week Range
Low: $0.91
High: $4.12
on April 7, 2025
on September 18, 2024
All-Time High: $99.95 on January 4, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$231.1M
EPS
-2.84
P/E Ratio (TTM)
-0.89
Forward P/E
-1.09
P/B Ratio
11.68
PEG Ratio
0.04
Div. Yield
N/A
ROE
-188.58%
Beta
2.197
Debt to Equity
110.14
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-711.63%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-33.76%
Return on Equity (TTM)
-188.58%
EBITDA
$-154.1M
Net Income (TTM)
$-236.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.47
Quarterly Revenue Growth (YoY)
597.50%
Quarterly Earnings Growth (YoY)
597.47%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Editas Medicine EDIT | 231.09M Micro-cap | -8.21% | -0.77% | 40.44% | 33.85% | 96.18% | -31.28% | -82.67% | -91.57% |
| Vertex VRTX | 99.55B Large-cap | -1.04% | -16.52% | -12.54% | -18.50% | -3.63% | -21.15% | 39.13% | 46.72% |
| Regeneron REGN | 62.21B Large-cap | -1.49% | 4.04% | -4.08% | -16.89% | -18.80% | -50.98% | 0.01% | 0.06% |
| Silence Therapeutics SLN | 244.20M Micro-cap | -10.09% | -22.42% | -19.02% | 6.89% | -33.10% | -74.80% | -54.58% | -75.33% |
| Alector ALEC | 237.85M Micro-cap | -6.75% | 45.96% | 65.49% | 43.29% | 24.34% | -55.49% | -77.53% | -81.06% |
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
Ownership & Short Interest
Insider Ownership
0.31%
Institutional Ownership
49.12%
Shares Short
8M
Short Ratio
3.37
Short % of Shares Outstanding
9.14%
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Editas Medicine Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Editas Medicine would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is EDIT's 52-week high and low?
- In the last 52 weeks, Editas Medicine reached a high of $4.12 (on September 18, 2024) and a low of $0.91 (on April 7, 2025).
- What is the market cap and P/E ratio for EDIT?
- Curious about Editas Medicine's size and valuation? Its market capitalization stands at 231.09M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.89, and the forward P/E (looking ahead) is -1.09.
- Does EDIT pay dividends? If so, what's the yield?
- As for dividends, Editas Medicine isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Editas Medicine's main competitors or similar companies to consider before investing?
When looking at Editas Medicine, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX99.55B Healthcare Biotechnology -21.15% 39.13% Regeneron
REGN62.21B Healthcare Biotechnology -50.98% 0.01% Silence Therapeutics
SLN244.20M Healthcare Biotechnology -74.80% -54.58% Alector
ALEC237.85M Healthcare Biotechnology -55.49% -77.53% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Editas Medicine Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Editas Medicine's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -188.58%, the Debt to Equity ratio from the most recent quarter is 110.14, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for EDIT?
- Looking at Editas Medicine's growth, its revenue over the trailing twelve months (TTM) was $39M. Compared to the same quarter last year (YoY), quarterly revenue grew by 597.50%, and quarterly earnings saw a YoY growth of 597.47%.
- How much of EDIT stock is held by insiders and institutions?
- Wondering who owns Editas Medicine stock? Company insiders (like executives and directors) hold about 0.31% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 49.12%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.